Abstract
Antibodies and anticancer drug-antibody conjugates used in experimental cancer research or clinically must be freeze-dried for preserving the activity and storage at room temperature. This often results in some denaturation and loss of activity . We describe a recovery of the cytotoxic activity of a paclitaxel-mAb immunoconjugate after freeze-drying. The paclitaxel-antibody conjugate specific for ovarian cancer was tested both for its cytotoxicity in vitro and immunological activity after freeze drying in the presence of various preservatives. Results show that the inclusion of trehalose as a stabilizer at concentrations varying from the 0.25 and 0.40M protected the antibody and saved the pharmacological activity. When PEG alone or with trehalose was used, the immunological and cytotoxic activities recovery were lower. Albumin was not protective. This study shows that the addition of trehalose for freeze drying labile drug is a promising method for storage of large quantities of the immunoconjugates for experimental and therapeutic use.
Keywords: lyophilization, freeze drying, paclitaxel immunoconjugates, drug targeting, monoclonal antibody, cytotoxicity, trehalose
Current Medicinal Chemistry
Title: Paclitaxel Antibody Conjugates and Trehalose for Preserving the Immunulogical Activity After Freeze-Drying
Volume: 11 Issue: 4
Author(s): Jairo Jaime and Michel Page
Affiliation:
Keywords: lyophilization, freeze drying, paclitaxel immunoconjugates, drug targeting, monoclonal antibody, cytotoxicity, trehalose
Abstract: Antibodies and anticancer drug-antibody conjugates used in experimental cancer research or clinically must be freeze-dried for preserving the activity and storage at room temperature. This often results in some denaturation and loss of activity . We describe a recovery of the cytotoxic activity of a paclitaxel-mAb immunoconjugate after freeze-drying. The paclitaxel-antibody conjugate specific for ovarian cancer was tested both for its cytotoxicity in vitro and immunological activity after freeze drying in the presence of various preservatives. Results show that the inclusion of trehalose as a stabilizer at concentrations varying from the 0.25 and 0.40M protected the antibody and saved the pharmacological activity. When PEG alone or with trehalose was used, the immunological and cytotoxic activities recovery were lower. Albumin was not protective. This study shows that the addition of trehalose for freeze drying labile drug is a promising method for storage of large quantities of the immunoconjugates for experimental and therapeutic use.
Export Options
About this article
Cite this article as:
Jaime Jairo and Page Michel, Paclitaxel Antibody Conjugates and Trehalose for Preserving the Immunulogical Activity After Freeze-Drying, Current Medicinal Chemistry 2004; 11 (4) . https://dx.doi.org/10.2174/0929867043455954
DOI https://dx.doi.org/10.2174/0929867043455954 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Current Medicinal Chemistry Back Pain in Children and Adolescents: Etiology, Clinical Approach and Treatment
Current Pediatric Reviews Signal Transduction Targets in Prostate Cancer
Current Signal Transduction Therapy Bothrops pauloensis Snake Venom Toxins: The Search for New Therapeutic Models
Current Topics in Medicinal Chemistry The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets Upregulation of DLX2 Confers a Poor Prognosis in Glioblastoma Patients by Inducing a Proliferative Phenotype
Current Molecular Medicine Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Patent Selections
Recent Patents on Mechanical Engineering Application of Proteomics to the Discovery of Cancer Biomarkers
Current Cancer Therapy Reviews Vitamin D Receptor is a Novel Drug Target for Ovarian Cancer Treatment
Current Cancer Drug Targets Targets for Steroid Hormone Mediated Actions of Periodontal Pathogens, Cytokines and Therapeutic Agents Some Implications on Tissue Turnover in the Periodontium
Current Drug Targets Withdrawal Notice: Circulatory Cells as Tumortropic Carrier for Targetability Improvement
Current Drug Delivery Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry A Review of the Possible Mechanisms of Action of Tocotrienol – A Potential Antiosteoporotic Agent
Current Drug Targets Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry